Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". (Q45168949)
Jump to navigation
Jump to search
scientific article published on 22 November 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". |
scientific article published on 22 November 2004 |
Statements
1 reference
Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". (English)
1 reference
Joseph D Piorkowski
1 reference
22 November 2004
1 reference
1 reference
292
1 reference
21
1 reference
2655-7; discussion 2658-9
1 reference
Identifiers
1 reference
1 reference